AI assistant
RPG Life Sciences Limited — Earnings Release 2021
Oct 30, 2020
60243_rns_2020-10-30_01ff5299-754f-4626-b93f-73b28ade2bb6.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [506 x 98] intentionally omitted <==
October 30, 2020
The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051
BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol: RPGLIFE
Scrip Code: 532983
Dear Sirs,
Sub: Press Release - Financial Results
Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2020.
Kindly take the above on record.
Thanking you,
Yours Sincerely, For RPG Life Sciences Limited
==> picture [92 x 30] intentionally omitted <==
Rajesh Shirambekar Head – Legal & Company Secretary
==> picture [85 x 79] intentionally omitted <==
Encl.: as above
==> picture [531 x 56] intentionally omitted <==
==> picture [160 x 78] intentionally omitted <==
Quarter 2 PBT grew by 22% Y‐o‐Y and 15% Q‐o‐Q. Revenue from operations grew by 6% Q‐o‐Q.
Mumbai, 30[th] October, 2020 : RPG Life Sciences Limited has announced its financial results for the second quarter and half year ending on 30[th] September, 2020.
| Quarter 2 PBT grew by 22% Y‐o‐Y and 15% Q‐o‐Q.Revenue from operations grew by 6% Q‐o‐Q. | Quarter 2 PBT grew by 22% Y‐o‐Y and 15% Q‐o‐Q.Revenue from operations grew by 6% Q‐o‐Q. | Quarter 2 PBT grew by 22% Y‐o‐Y and 15% Q‐o‐Q.Revenue from operations grew by 6% Q‐o‐Q. | Quarter 2 PBT grew by 22% Y‐o‐Y and 15% Q‐o‐Q.Revenue from operations grew by 6% Q‐o‐Q. | Quarter 2 PBT grew by 22% Y‐o‐Y and 15% Q‐o‐Q.Revenue from operations grew by 6% Q‐o‐Q. | Quarter 2 PBT grew by 22% Y‐o‐Y and 15% Q‐o‐Q.Revenue from operations grew by 6% Q‐o‐Q. |
|---|---|---|---|---|---|
| Mumbai, 30th October, 2020: RPG Life Sciences Limited has announced its financial results for the sequarter and half year ending on 30thSeptember, 2020.Q2 FY 21 HighlightsYoY Net Revenue from OperationsYoY PBT from OperationsRs 97.13 crores – down from Rs 98.49croresRs 14.73 crores – up from Rs 12.0crores | |||||
| Q2 FY 21 Highlights | YoY Net Revenue from Operations | YoY PBT from Operations | |||
| Rs 97.13 crores – down from Rs 98.49crores | Rs 14.73 crores – up from Rs 12.0crores | ||||
| H1 FY 21 Highlights | Rs 188.78 crores – down from Rs 192.53crores | Rs 27.56 crores – up from Rs 22.90crores |
RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 22% Y‐o‐Y and by 15% Q‐o‐Q for Q2 FY 21, resulting in maintaining the upward trajectory in EBITDA margins, which improved from 16.8% to 19.7% Y‐o‐Y. Revenue from Operations at Rs 97.13 crores registered a decline of 1% Y‐o‐Y and a growth of 6% Q‐o‐Q for Q2 FY 21. For H1 FY 21, too, EBITDA margins improved from 16.7% to 19.3% Y‐o‐Y despite a decline of 2% Y‐o‐Y in Revenues from Operations at Rs 188.78 crores.
Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “The overall performance of the Company in the second quarter and first half of this fiscal has been relatively good considering the magnitude of disruptions caused by the extended Covid‐19 pandemic. Profits grew by 22% and 20% respectively and EBITDA margins retained their upward trajectory despite a marginal decline in sales Y‐o‐Y for both Q2 and H1. The revenues grew by 6% Q‐o‐Q. Focus on profitable product mix, sustained opex control measures and bringing in efficiency in manufacturing operations has helped in improving the overall profitability. Domestic Formulations, the biggest contributor to our business, will continue to be our thrust area. The measures that contributed to our turnaround last year will continue to drive our operations; these measures include product portfolio augmentation, life cycle management of our ‘text book’ brand assets, sales force effectiveness, sales hygiene and opex control.”
RPG Life Sciences Ltd (www.rpglifesciences.com):
RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research‐based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.
RPG Enterprises (www.rpggroup.com):
RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation‐led technology businesses.
Media Contact:
Sumeet Chatterjee
Senior Vice President – Corporate Brand and Group Communications +91 9820340650 | [email protected]
==> picture [74 x 71] intentionally omitted <==